Clinical Trials in Wollstonecraft, Australia
3 recruiting
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Advanced Solid Tumor
BioNTech SE980 enrolled53 locationsNCT07070232
Recruiting
Phase 2
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Malignant Melanoma
Merck Sharp & Dohme LLC160 enrolled38 locationsNCT06961006
Recruiting
Phase 3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Advanced Melanoma
Immunocore Ltd680 enrolled211 locationsNCT06112314
Recruiting
Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Advanced Melanoma
Immunocore Ltd540 enrolled82 locationsNCT05549297
Recruiting
Phase 1
Study of IMC-P115C in Advanced PRAME-Positive Cancers
CancerPRAME PositiveHLA-A*02:01-positive
Immunocore Ltd140 enrolled13 locationsNCT07156136
Recruiting
Phase 2
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Cutaneous MelanomaMucosal Melanoma
Melanoma Institute Australia494 enrolled1 locationNCT06999980
Recruiting
Not Applicable
The Multicentre Selective Lymphadenectomy Trial - 3
Cutaneous Melanoma, Stage III
Melanoma Institute Australia1,500 enrolled6 locationsNCT07049276
Recruiting
Phase 2
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Merkel Cell Carcinoma
Melanoma Institute Australia20 enrolled1 locationNCT06151236
Recruiting
Phase 2
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Melanoma Metastatic
Melanoma Institute Australia129 enrolled4 locationsNCT06767306
Recruiting
Phase 2
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Melanoma Stage IV
Melanoma Institute Australia218 enrolled9 locationsNCT03340129
Recruiting
Phase 2
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Melanoma Institute Australia20 enrolled1 locationNCT06288191
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Advanced Solid Tumor
Strand Therapeutics Inc.108 enrolled7 locationsNCT06249048